Publication & Citation Trends
Publications
44 total
An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy.
Cited by 1
Semantic Scholar
Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity
Cited by 1
Semantic Scholar
Abstract 1833: Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity
Cited by 0
Semantic Scholar
Abstract 2824: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance anti-GPC3 CAR T cells to drive complete responses in solid epithelial tumor models
Cited by 1
Semantic Scholar
An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma
Cited by 60
Semantic Scholar
Abstract 1744: STK-012, an alpha/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor
Cited by 11
Semantic Scholar
Abstract 1512: OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumor efficacy by driving T cell expansion and fitness
Cited by 0
Semantic Scholar
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab
Cited by 14
Semantic Scholar
Research Topics
RNA and protein synthesis mechanisms
(9)
Immune Cell Function and Interaction
(8)
CAR-T cell therapy research
(8)
Immunotherapy and Immune Responses
(6)
Viral Infectious Diseases and Gene Expression in Insects
(6)
Affiliations
Leiden University
Merck & Co., Inc., Rahway, NJ, USA (United States)
Rijksmuseum
Genetic Information Research Institute
Palo Alto Research Center